產品屬性：
產品名稱 | BPR1K871 |
規格 | 100mg、250mg、500mg |
貨號 | EY-01Y12876 |
Cas No.: N/A
別名: N/A
化學名: N/A
分子式: C25H28ClN7O2S
分子量: 526.05
溶解度: DMSO: 125 mg/mL (237.62 mM)
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy[1].IC50: 19 nM (FLT3), 22 nM (AURKA)[1]BPR1K871 shows potent anti-proliferative activities in MOLM-13 and MV4-11 AML cells with an EC50 of ~ 5 nM[1].BPR1K871 is a multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and solid tumors[1].[1]. Hsu YC, et al. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. 2016 Dec 27; 7(52): 86239-86256.
特別提醒公司產品僅供科研使用
